4 assets in Monoclonal Gammopathy Of Uncertain Significance

Therapeutic assets addressing Monoclonal Gammopathy Of Uncertain Significance, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Isatuximab Monoclonal Gammopathy Of Uncertain Significance	Assistance Publique - Hôpitaux de Paris	P2	CCC (53)
Linvoseltamab Monoclonal Gammopathy Of Uncertain Significance	Regeneron Pharmaceuticals	P2	CCC (53)
Metformin Monoclonal Gammopathy Of Uncertain Significance	Dana-Farber Cancer Institute	P2	CCC (53)
Florbetaben Monoclonal Gammopathy Of Uncertain Significance	University of Zurich	N/A	D (30)